← Evidence library

BIB_196

NICE TA837 — Pembrolizumab for adjuvant treatment of completely resected stage IIB or IIC melanoma. 2022. KEYNOTE-716 evidence basis. [Tasks: 19a, 18] Tier: 2 Grade: N/A Retrieved: 2026-05-07

Evidence grade

N/A

Tier

2

Cited by tasks

19a, 18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_196/findings.md (research corpus). This page is a short context summary — not individualised medical advice.